Tseng L F, Collins K A, Portoghese P S
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226.
Life Sci. 1993;52(19):PL211-5. doi: 10.1016/0024-3205(93)90062-8.
The antinociception induced by beta-endorphin given intracerebroventricularly (i.c.v.) has been previously demonstrated to be mediated by the release of Met-enkephalin and subsequent stimulation of delta receptors in the spinal cord for antinociception. The present study was designed to determine what type of opioid receptor, delta 1 or delta 2, in the spinal cord is involved in i.c.v. beta-endorphin-induced antinociception. Antinociception was assessed by the tail-flick test in male ICR mice. NTB (0.2-20 nmol) and NTI (0.22-2.2 nmol), selective delta 2 receptor antagonists, given intrathecally (i.t.) dose-dependently attenuated i.c.v. beta-endorphin-induced inhibition of the tail-flick response. On the other hand, BNTX (0.02-2.2 nmol), a selective delta 1 receptor antagonist, given i.t., did not block i.c.v. beta-endorphin-induced antinociception. The tail-flick inhibition induced by DAMGO, a mu receptor agonist, or U50,488H, a kappa receptor agonist, was not blocked by i.t. BNTX, NTB or NTI. It is concluded that delta 2 but not delta 1 receptors in the spinal cord are involved in i.c.v. beta-endorphin-induced antinociception.
先前已证明,脑室内注射β-内啡肽所诱导的镇痛作用是通过甲硫氨酸脑啡肽的释放以及随后对脊髓中δ受体的刺激来介导的,从而产生镇痛效果。本研究旨在确定脊髓中哪种类型的阿片受体(δ1或δ2)参与了脑室内注射β-内啡肽诱导的镇痛作用。通过对雄性ICR小鼠进行甩尾试验来评估镇痛效果。鞘内注射选择性δ2受体拮抗剂NTB(0.2 - 20 nmol)和NTI(0.22 - 2.2 nmol)可剂量依赖性地减弱脑室内注射β-内啡肽诱导的甩尾反应抑制。另一方面,鞘内注射选择性δ1受体拮抗剂BNTX(0.02 - 2.2 nmol)并不阻断脑室内注射β-内啡肽诱导的镇痛作用。μ受体激动剂DAMGO或κ受体激动剂U50,488H所诱导的甩尾抑制不受鞘内注射BNTX、NTB或NTI的阻断。得出的结论是,脊髓中的δ2受体而非δ1受体参与了脑室内注射β-内啡肽诱导的镇痛作用。